Melvin J Silverstein1,2, Melinda Epstein3, Brian Kim4, Kevin Lin4, Sadia Khan5, Lincoln Snyder5, Lisa Guerra5, Colleen Coleman5, Peter Chen4. 1. Department of Surgery, Hoag Memorial Hospital Presbyterian, Newport Beach, CA, USA. melsilver9@gmail.com. 2. Keck School of Medicine, University of Southern California, Los Angeles, USA. melsilver9@gmail.com. 3. Department of Clinical Research, Hoag Memorial Hospital Presbyterian, Newport Beach, CA, USA. 4. Department of Radiation Oncology, Hoag Memorial Hospital Presbyterian, Newport Beach, CA, USA. 5. Department of Surgery, Hoag Memorial Hospital Presbyterian, Newport Beach, CA, USA.
Abstract
BACKGROUND: Two prospective, randomized trials, TARGIT-A and ELIOT, have shown intraoperative radiation therapy to be a safe alternative, with a low-risk of local recurrence, compared with whole breast radiation therapy, following breast-conserving surgery, for selected low-risk patients. We report the first 1000 tumors treated with this modality at our facility. METHODS: A total of 1000 distinct breast cancers in 984 patients (16 bilateral) were treated with breast conserving surgery and X-ray IORT from June 2010 to August 2017. Patients were enrolled in an IORT registry trial. Local recurrence was the primary endpoint. RESULTS: There have been 28 ipsilateral local recurrences, ten DCIS and 18 invasive. Four local recurrences were within the IORT field, 13 outside of the IORT field but within the same quadrant as the index cancer, and 11 were new cancers in different quadrants. There have been four regional nodal recurrences and one distant recurrence. There have been no breast cancer related deaths and 14 non-breast cancer deaths. With a median follow-up of 36 months, Kaplan-Meier analysis projects 3.9% of patients will recur locally at 4 years. This includes all ipsilateral events in all quadrants. CONCLUSIONS: The local, regional, and distant recurrence rates observed in this trial were comparable to those of the prospective randomized TARGIT-A and ELIOT trials. The low complication rates previously reported by our group as well as the low recurrence rates reported in this study support the cautious use and continued study of X-ray IORT in women with low-risk breast cancer.
BACKGROUND: Two prospective, randomized trials, TARGIT-A and ELIOT, have shown intraoperative radiation therapy to be a safe alternative, with a low-risk of local recurrence, compared with whole breast radiation therapy, following breast-conserving surgery, for selected low-risk patients. We report the first 1000 tumors treated with this modality at our facility. METHODS: A total of 1000 distinct breast cancers in 984 patients (16 bilateral) were treated with breast conserving surgery and X-ray IORT from June 2010 to August 2017. Patients were enrolled in an IORT registry trial. Local recurrence was the primary endpoint. RESULTS: There have been 28 ipsilateral local recurrences, ten DCIS and 18 invasive. Four local recurrences were within the IORT field, 13 outside of the IORT field but within the same quadrant as the index cancer, and 11 were new cancers in different quadrants. There have been four regional nodal recurrences and one distant recurrence. There have been no breast cancer related deaths and 14 non-breast cancer deaths. With a median follow-up of 36 months, Kaplan-Meier analysis projects 3.9% of patients will recur locally at 4 years. This includes all ipsilateral events in all quadrants. CONCLUSIONS: The local, regional, and distant recurrence rates observed in this trial were comparable to those of the prospective randomized TARGIT-A and ELIOT trials. The low complication rates previously reported by our group as well as the low recurrence rates reported in this study support the cautious use and continued study of X-ray IORT in women with low-risk breast cancer.
Authors: Annie Tang; Caitlin M Cohan; Genna Beattie; Elizabeth L Cureton; Jonathan D Svahn; Liisa L Lyon; Jason F Kelly; Veronica C Shim Journal: Ann Surg Oncol Date: 2021-03-09 Impact factor: 5.344
Authors: Lee C Goddard; N Patrik Brodin; Amar Basavatia; Maureen McEvoy; Sheldon Feldman; Jana Fox; Keyur J Mehta; Wolfgang A Tomé Journal: Cureus Date: 2018-12-05
Authors: Fantine Giap; Lillie O'steen; I-Chia Liu; Lisa E Spiguel; Christiana M Shaw; Christopher G Morris; Raymond B Mailhot Vega; Judith L Lightsey; Julie A Bradley; Nancy P Mendenhall; Paul G Okunieff; Natalie A Lockney Journal: Rep Pract Oncol Radiother Date: 2022-09-19
Authors: Ana Alicia Tejera Hernández; Víctor Manuel Vega Benítez; Juan Carlos Rocca Cardenas; Neith Ortega Pérez; Nieves Rodriguez Ibarria; Juan Carlos Díaz Chico; Juan José García-Granados Alayón; Pedro Pérez Correa; Juan Ramón Hernández Hernández Journal: Ann Surg Treat Res Date: 2020-05-28 Impact factor: 1.766
Authors: Melvin J Silverstein; Melinda S Epstein; Peter Chen; Kevin Lin; Sadia Khan; Lincoln Snyder; Colleen Coleman; Lisa Guerra; Farideh Dehkordi-Vakil; Brian Kim Journal: Ann Surg Oncol Date: 2022-01-22 Impact factor: 4.339